oxervate
dompe farmaceutici s.p.a. - recombinant human nerve growth factor - keratitis - ophthalmologica - behandeling van matig (persistent epitheliaal defect) of ernstig (hoornvlieszweer) neurotrofische keratitis bij volwassenen.
humuline 30/70 cartridge 100 ie/ml inj. susp. s.c./i.m. patr.
eli lilly benelux sa-nv - humane insuline 100 ie/ml - suspensie voor injectie in een patroon - 100 iu/ml - humane, recombinante insuline 30 ie/ml; insuline isofaan 70 ie/ml - insulin (human)
mycograb
neutec pharma plc - recombinant humaan monoklonaal antilichaam met hsp - candidiasis - antimycotica voor systemisch gebruik - de behandeling van invasieve candidiasis bij volwassen patiënten, in combinatie met amfotericine b of een lipide formulering van amfotericine b.
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccins - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - varkens - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccins - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.
fatrovax rhd
fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - immunologicals voor leporidae - konijnen - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.
oncept il-2, lyofilisaat en suspendeervloeistof voor suspensie voor injectie voor katten
boehringer ingelheim vetmedica gmbh - feliene interleukine recombinant kannariepokkenvirus vcp1338 - lyofilisaat voor suspensie voor injectie - feliene interleukine recombinant kannariepokkenvirus vcp1338 6 e/ml, - other immunostimulants - katten
abrysvo
pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - respiratoire syncytiële virusinfecties - vaccins - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. zie hoofdstuk 4. 2 en 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.
alpheon
biopartners gmbh - recombinant human interferon alfa-2a - hepatitis c, chronisch - immunostimulants, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.